On the public citation graph

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer

https://doi.org/10.1053/j.gastro.2010.02.005
0 signed · 188 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/14651858.cd005392.pub3openalex-snapshot
Anti-angiogenic therapies for metastatic colorectal cancer
inferredcites →https://doi.org/10.1002/cncr.22915openalex-snapshot
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
inferredcites →https://doi.org/10.1002/jso.20301openalex-snapshot
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
inferredcites →https://doi.org/10.1007/s00280-008-0852-1openalex-snapshot
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients
inferredcites →https://doi.org/10.1016/j.critrevonc.2009.06.005openalex-snapshot
Integration of panitumumab into the treatment of colorectal cancer
inferredcites →https://doi.org/10.1016/j.ctrv.2009.02.001openalex-snapshot
Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment
inferredcites →https://doi.org/10.1016/j.hoc.2004.06.002openalex-snapshot
Epidermal growth factor receptor in tumor angiogenesis
inferredcites →https://doi.org/10.1016/s0002-9440(10)64739-6openalex-snapshot
Vasculogenic Mimicry and Tumor Angiogenesis
inferredcites →https://doi.org/10.1016/s0021-9258(18)99049-6openalex-snapshot
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
inferredcites →https://doi.org/10.1016/s0065-230x(08)60765-4openalex-snapshot
Signal Transduction through MAP Kinase Cascades
inferredcites →https://doi.org/10.1016/s0092-8674(00)80674-1openalex-snapshot
The Multiple Roles of PTEN in Tumor Suppression
inferredcites →https://doi.org/10.1016/s0093-7754(01)90283-0openalex-snapshot
Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839
inferredcites →https://doi.org/10.1016/s0955-0674(98)80149-xopenalex-snapshot
Mechanisms and consequences of activation of protein kinase B/Akt
inferredcites →https://doi.org/10.1016/s1050-1738(00)00046-3openalex-snapshot
Eph Receptors and Ephrin Ligands Essential Mediators of Vascular Development
inferredcites →https://doi.org/10.1016/s1359-6349(09)71172-3openalex-snapshot
6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status
inferredcites →https://doi.org/10.1016/s1359-6349(09)72039-7openalex-snapshot
10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial
inferredcites →https://doi.org/10.1016/s1535-6108(02)00072-7openalex-snapshot
EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma
inferredcites →https://doi.org/10.1038/35052073openalex-snapshot
Untangling the ErbB signalling network
inferredcites →https://doi.org/10.1038/362841a0openalex-snapshot
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
inferredcites →https://doi.org/10.1038/nature05355openalex-snapshot
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
inferredcites →https://doi.org/10.1038/nm0603-669openalex-snapshot
The biology of VEGF and its receptors
inferredcites →https://doi.org/10.1038/nm1101-1194openalex-snapshot
Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
inferredcites →https://doi.org/10.1038/nm1294openalex-snapshot
Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells
inferredcites →https://doi.org/10.1038/nrc1093openalex-snapshot
Tumorigenesis and the angiogenic switch
inferredcites →https://doi.org/10.1038/nrclinonc.2009.110openalex-snapshot
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
inferredcites →https://doi.org/10.1038/sj.bjc.6603055openalex-snapshot
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
inferredcites →https://doi.org/10.1042/bj20091010openalex-snapshot
Angiopoietin-1-induced ubiquitylation of Tie2 by c-Cbl is required for internalization and degradation
inferredcites →https://doi.org/10.1053/j.seminoncol.2006.08.002openalex-snapshot
Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1056/nejm198612253152606openalex-snapshot
Tumors: Wounds That Do Not Heal
inferredcites →https://doi.org/10.1056/nejm200412303512724openalex-snapshot
Somatic Mutations ofEGFRin Colorectal Cancers and Glioblastomas
inferredcites →https://doi.org/10.1056/nejmoa032691openalex-snapshot
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1056/nejmoa033025openalex-snapshot
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1056/nejmoa0804385openalex-snapshot
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
inferredcites →https://doi.org/10.1056/nejmra0707704openalex-snapshot
EGFR Antagonists in Cancer Treatment
inferredcites →https://doi.org/10.1073/pnas.172398299openalex-snapshot
VEGF-Trap: A VEGF blocker with potent antitumor effects
inferredcites →https://doi.org/10.1073/pnas.80.5.1337openalex-snapshot
Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.
inferredcites →https://doi.org/10.1093/annonc/mdl469openalex-snapshot
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer
inferredcites →https://doi.org/10.1093/annonc/mdl481openalex-snapshot
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study
inferredcites →https://doi.org/10.1093/annonc/mdm124openalex-snapshot
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer
inferredcites →https://doi.org/10.1093/annonc/mdn368openalex-snapshot
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer
inferredcites →https://doi.org/10.1093/annonc/mdn637openalex-snapshot
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
inferredcites →https://doi.org/10.1097/ppo.0b013e318178d9deopenalex-snapshot
Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies
inferredcites →https://doi.org/10.1126/science.1079562openalex-snapshot
Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1
inferredcites →https://doi.org/10.1158/0008-5472.can-06-0191openalex-snapshot
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-1846openalex-snapshot
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
inferredcites →https://doi.org/10.1158/1078-0432.ccr-06-1627openalex-snapshot
Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors
inferredcites →https://doi.org/10.1158/1078-0432.ccr-07-1509openalex-snapshot
Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
inferredcites →https://doi.org/10.1158/1078-0432.ccr-07-5165openalex-snapshot
Polymorphisms inCyclooxygenase-2andEpidermal Growth Factor ReceptorAre Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-1014openalex-snapshot
A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-09-1070openalex-snapshot
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
inferredcites →https://doi.org/10.1158/1541-7786.mcr-06-0404openalex-snapshot
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
inferredcites →https://doi.org/10.1172/jci117857openalex-snapshot
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
inferredcites →https://doi.org/10.1200/jco.2001.19.3.843openalex-snapshot
Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer
inferredcites →https://doi.org/10.1200/jco.2002.03.100openalex-snapshot
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
inferredcites →https://doi.org/10.1200/jco.2003.01.504openalex-snapshot
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
inferredcites →https://doi.org/10.1200/jco.2003.10.066openalex-snapshot
Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2004.10.182openalex-snapshot
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
inferredcites →https://doi.org/10.1200/jco.2005.01.388openalex-snapshot
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
inferredcites →https://doi.org/10.1200/jco.2005.03.0536openalex-snapshot
Randomized Phase II Trial of the Clinical and Biological Effects of Two Dose Levels of Gefitinib in Patients With Recurrent Colorectal Adenocarcinoma
inferredcites →https://doi.org/10.1200/jco.2005.06.081openalex-snapshot
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
inferredcites →https://doi.org/10.1200/jco.2005.08.359openalex-snapshot
Phase II Study of Gefitinib, Fluorouracil, Leucovorin, and Oxaliplatin Therapy in Previously Treated Patients With Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2005.23.16_suppl.lba3openalex-snapshot
A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1)
inferredcites →https://doi.org/10.1200/jco.2006.06.7595openalex-snapshot
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
inferredcites →https://doi.org/10.1200/jco.2006.08.1620openalex-snapshot
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2006.08.8021openalex-snapshot
FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab
inferredcites →https://doi.org/10.1200/jco.2006.09.6305openalex-snapshot
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
inferredcites →https://doi.org/10.1200/jco.2007.12.0949openalex-snapshot
Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study
inferredcites →https://doi.org/10.1200/jco.2007.13.1193openalex-snapshot
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2007.14.7116openalex-snapshot
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2007.14.9930openalex-snapshot
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
inferredcites →https://doi.org/10.1200/jco.2007.15.4138openalex-snapshot
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
inferredcites →https://doi.org/10.1200/jco.2007.25.18_suppl.4000openalex-snapshot
Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
inferredcites →https://doi.org/10.1200/jco.2007.25.18_suppl.4033openalex-snapshot
Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo
inferredcites →https://doi.org/10.1200/jco.2007.25.18_suppl.4035openalex-snapshot
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study
inferredcites →https://doi.org/10.1200/jco.2008.16.3212openalex-snapshot
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
inferredcites →https://doi.org/10.1200/jco.2008.18.0786openalex-snapshot
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.4000openalex-snapshot
KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.4001openalex-snapshot
Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)
inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.4027openalex-snapshot
Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial
inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.4064openalex-snapshot
Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results
inferredcites →https://doi.org/10.1200/jco.2008.26.15_suppl.lba4011openalex-snapshot
Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)
inferredcites →https://doi.org/10.1200/jco.2009.21.9220openalex-snapshot
Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer
inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.4068openalex-snapshot
Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial
inferredcites →https://doi.org/10.1200/jco.2009.27.15_suppl.lba4openalex-snapshot
A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08
inferredcites →https://doi.org/10.3816/ccc.2006.n.037openalex-snapshot
Phase I Study of Gefitinib plus FOLFIRI in Previously Untreated Patients with Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.3816/ccc.2007.n.011openalex-snapshot
Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.5483/bmbrep.2008.41.4.278openalex-snapshot
Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis
inferredcites →https://doi.org/10.7270/q2dr317mopenalex-snapshot
BindingDB Entry 50022536: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4603279openalex-extracted
Efficacy of First-Line Immunization and Targeted Therapy in Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis
inferred← citeshttps://doi.org/10.2139/ssrn.4611835openalex-extracted
Efficacy of First-Line Immunization and Targeted Therapy in Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis
inferred← citeshttps://doi.org/10.2139/ssrn.4750450openalex-extracted
Efficacy of First-Line Immunization and Targeted Therapy in Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis
inferred← citeshttps://doi.org/10.1002/eji.201141825openalex-snapshot
Macrophages in human colorectal cancer are pro‐inflammatory and prime T cells towards an anti‐tumour type‐1 inflammatory response
inferred← citeshttps://doi.org/10.1002/ijc.25841openalex-snapshot
Frequent genomic loss at chr16p13.2 is associated with poor prognosis in colorectal cancer
inferred← citeshttps://doi.org/10.1002/ijc.28542openalex-snapshot
Adrenomedullin is a therapeutic target in colorectal cancer
inferred← citeshttps://doi.org/10.1002/ijc.34256openalex-snapshot
Research advances in nanomedicine applied to the systemic treatment of colorectal cancer
inferred← citeshttps://doi.org/10.1002/jcb.24173openalex-snapshot
N‐glycan biosynthesis inhibitors induce in vitro anticancer activity in colorectal cancer cells
inferred← citeshttps://doi.org/10.1002/mc.21892openalex-snapshot
Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma
inferred← citeshttps://doi.org/10.1007/978-1-4614-6015-2_1openalex-snapshot
Mechanisms of Gastrointestinal Carcinogenesis
inferred← citeshttps://doi.org/10.1007/978-1-4614-6015-2_9openalex-snapshot
Cancers of the Rectum and Anal Canal
inferred← citeshttps://doi.org/10.1007/978-3-030-63369-1_11openalex-snapshot
Targeting Angiogenesis for Colorectal Cancer Therapy
inferred← citeshttps://doi.org/10.1007/s00210-012-0818-zopenalex-snapshot
3′,4′-Dimethoxythioflavone induces endothelium-dependent vasorelaxation through activation of epidermal growth factor receptor
inferred← citeshttps://doi.org/10.1007/s10456-011-9231-3openalex-snapshot
Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
inferred← citeshttps://doi.org/10.1007/s10456-013-9336-yopenalex-snapshot
p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-κB pathway
inferred← citeshttps://doi.org/10.1007/s10555-010-9241-4openalex-snapshot
The role of nutraceutical proteins and peptides in apoptosis, angiogenesis, and metastasis of cancer cells
inferred← citeshttps://doi.org/10.1007/s10585-013-9604-7openalex-snapshot
Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met
inferred← citeshttps://doi.org/10.1007/s11377-010-0425-9openalex-snapshot
Zielgerichtete Therapie gastrointestinaler Tumoren
inferred← citeshttps://doi.org/10.1007/s11888-012-0148-zopenalex-snapshot
Colon Cancer Liver Metastasis: Addition of Antiangiogenesis or EGFR Inhibitors to Chemotherapy
inferred← citeshttps://doi.org/10.1007/s13277-014-2726-yopenalex-snapshot
Nrdp1 inhibits metastasis of colorectal cancer cells by EGFR signaling-dependent MMP7 modulation
inferred← citeshttps://doi.org/10.1016/b978-0-12-386503-8.00004-1openalex-snapshot
Guidance for Life, Cell Death, and Colorectal Neoplasia by Netrin Dependence Receptors
inferred← citeshttps://doi.org/10.1016/b978-0-323-07155-0.00018-6openalex-snapshot
Cellular Growth Control and Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-443-23908-3.00012-5openalex-snapshot
Liver cancer: insulin signal transduction pathway dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
inferred← citeshttps://doi.org/10.1016/b978-1-63067-036-8.00017-2openalex-snapshot
What Are the Physiological Roles of Mead Acid (5,8,11-Eicosatrienoic Acid)? * *This chapter exploring the physiological roles of 5,8,11-eicosatrienoic acid (20:3n-9, Mead acid, MA) consists of two parts. Part 1 examines the effects of MA on two types of essential bone cells, osteoclasts and…
inferred← citeshttps://doi.org/10.1016/j.canlet.2021.05.040openalex-snapshot
Protease-activated receptor 2 stabilizes Bcl-xL and regulates EGFR–targeted therapy response in colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.clcc.2011.06.010openalex-snapshot
Panitumumab in Combination With Cytotoxic Chemotherapy for the Treatment of Metastatic Colorectal Carcinoma
inferred← citeshttps://doi.org/10.1016/j.clon.2024.103700openalex-snapshot
Fruquintinib Combined With PD-1 Inhibitors for the Treatment of the Patients With Microsatellite Stability Metastatic Colorectal Cancer: Real-World Data
inferred← citeshttps://doi.org/10.1016/j.ebiom.2015.03.019openalex-snapshot
Aspirin Prevents Colorectal Cancer by Normalizing EGFR Expression
inferred← citeshttps://doi.org/10.1016/j.ejphar.2022.175152openalex-snapshot
Role of a mixed probiotic product, VSL#3, in the prevention and treatment of colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.gendis.2025.101800openalex-snapshot
MFAP2 promotes metastasis and drug resistance by regulating epithelial-to-mesenchymal transition through EGFR signaling pathway in colorectal cancer cells
inferred← citeshttps://doi.org/10.1016/j.jare.2024.11.024openalex-snapshot
Interleukin-10 deficiency suppresses colorectal cancer metastasis by enriching gut Parabacteroides distasonis
inferred← citeshttps://doi.org/10.1016/j.jpba.2013.03.010openalex-snapshot
Determination of henatinib in human plasma and urine by liquid chromatography–tandem mass spectrometry and its pharmacokinetic application
inferred← citeshttps://doi.org/10.1016/j.jvir.2013.04.023openalex-snapshot
Cancer Concepts and Principles: Primer for the Interventional Oncologist—Part II
inferred← citeshttps://doi.org/10.1016/j.jvir.2013.04.024openalex-snapshot
Cancer Concepts and Principles: Primer for the Interventional Oncologist—Part I
inferred← citeshttps://doi.org/10.1016/j.neo.2014.09.008openalex-snapshot
E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts
inferred← citeshttps://doi.org/10.1016/j.nut.2011.03.004openalex-snapshot
Dietary walnuts inhibit colorectal cancer growth in mice by suppressing angiogenesis
inferred← citeshttps://doi.org/10.1016/j.patbio.2011.02.002openalex-snapshot
Chronochimiothérapie à base de 5-fluorouracil, acide folinique et oxaliplatine administrée en deux jours toutes les deux semaines pour le cancer colorectal. L’expérience du CHC-Liège (Belgique)
inferred← citeshttps://doi.org/10.1016/j.plefa.2012.04.004openalex-snapshot
Inhibitory effect of 5,8,11-eicosatrienoic acid on angiogenesis
inferred← citeshttps://doi.org/10.1016/j.prp.2025.156346openalex-snapshot
NEK8 stabilization via USP51-mediated deubiquitination promotes colorectal cancer progression
inferred← citeshttps://doi.org/10.1016/j.trecan.2024.05.001openalex-snapshot
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.yexmp.2015.03.030openalex-snapshot
ZEB2 promotes vasculogenic mimicry by TGF-β1 induced epithelial-to-mesenchymal transition in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/s1155-1968(22)44636-0openalex-snapshot
10.1016/s1155-1968(22)44636-0
inferred← citeshttps://doi.org/10.1038/s41419-018-0490-4openalex-snapshot
MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway
inferred← citeshttps://doi.org/10.1038/srep06460openalex-snapshot
Testing an unusual in vivo vessel network model: a method to study angiogenesis in the colonial tunicate Botryllus schlosseri
inferred← citeshttps://doi.org/10.1053/j.gastro.2012.05.034openalex-snapshot
A Role for the Epidermal Growth Factor Receptor Signaling in Development of Intestinal Serrated Polyps in Mice and Humans
inferred← citeshttps://doi.org/10.1080/14737167.2016.1245618openalex-snapshot
Cost-effectiveness of cetuximab for colorectal cancer
inferred← citeshttps://doi.org/10.1080/17512433.2019.1630272openalex-snapshot
The clinical application of fruquintinib on colorectal cancer
inferred← citeshttps://doi.org/10.1084/jem.20131195openalex-snapshot
Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A
inferred← citeshttps://doi.org/10.1093/annonc/mds465openalex-snapshot
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study
inferred← citeshttps://doi.org/10.1093/jnci/djaa195openalex-snapshot
Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies
inferred← citeshttps://doi.org/10.1093/jnci/djs433openalex-snapshot
Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer
inferred← citeshttps://doi.org/10.1097/js9.0000000000002573openalex-snapshot
Colorectal cancer: the immune microenvironment and the gut microbiota – new perspectives, challenges, and opportunities
inferred← citeshttps://doi.org/10.1097/md.0000000000003762openalex-snapshot
Economic evaluation study (CHEER-compliant)
inferred← citeshttps://doi.org/10.1097/scs.0b013e31822e5cbdopenalex-snapshot
Long-Term Evaluation of Maxillary Reconstruction by Iliac Bone Graft
inferred← citeshttps://doi.org/10.1109/mci.2018.2840659openalex-snapshot
Identifying DNA Methylation Modules Associated with a Cancer by Probabilistic Evolutionary Learning
inferred← citeshttps://doi.org/10.1111/cas.14360openalex-snapshot
Upregulation of adipocyte enhancer‐binding protein 1 in endothelial cells promotes tumor angiogenesis in colorectal cancer
inferred← citeshttps://doi.org/10.1111/j.1349-7006.2011.02199.xopenalex-snapshot
Z inc finger E ‐box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial‐to‐mesenchymal transition
inferred← citeshttps://doi.org/10.1111/j.1600-0501.2011.02300.xopenalex-snapshot
Immunohistochemical analysis of matrix metalloproteinase‐9, vascular endothelial growth factor, bone sialoprotein and i‐nitric oxide synthase in calvaria vs. iliac crest bone grafts
inferred← citeshttps://doi.org/10.1111/jcmm.12486openalex-snapshot
Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT ‐29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth
inferred← citeshttps://doi.org/10.1155/2012/597497openalex-snapshot
Molecular Events in Primary and Metastatic Colorectal Carcinoma: A Review
inferred← citeshttps://doi.org/10.1155/2015/454279openalex-snapshot
Pien Tze Huang Inhibits Hypoxia-Induced Angiogenesis via HIF-1α/VEGF-A Pathway in Colorectal Cancer
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-13-1637openalex-snapshot
Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
inferred← citeshttps://doi.org/10.1158/1535-7163.mct-12-1162openalex-snapshot
Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
inferred← citeshttps://doi.org/10.1177/1934578x221126964openalex-snapshot
A Study on the Mechanism of Herbal Drug FDY003 for Colorectal Cancer Treatment by Employing Network Pharmacology
inferred← citeshttps://doi.org/10.1186/s12935-025-04146-6openalex-snapshot
NSC777201 exhibits anticancer activity against colorectal cancer cells by inducing multiple types of cell death
inferred← citeshttps://doi.org/10.1186/s13046-017-0524-2openalex-snapshot
Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels
inferred← citeshttps://doi.org/10.1309/ajcpu3j7fgayqbrlopenalex-snapshot
Endoscopic Ultrasound Fine-Needle Aspiration Cytology Mutation Profiling Using Targeted Next-Generation Sequencing
inferred← citeshttps://doi.org/10.1371/journal.pone.0023381openalex-snapshot
An RNA Interference Phenotypic Screen Identifies a Role for FGF Signals in Colon Cancer Progression
inferred← citeshttps://doi.org/10.1371/journal.pone.0117514openalex-snapshot
The Inhibitory Effects of Anacardic Acid on Hepatitis C Virus Life Cycle
inferred← citeshttps://doi.org/10.1371/journal.pone.0220902openalex-snapshot
Peripheral blood mononuclear cells extracts VEGF protein levels and VEGF mRNA: Associations with inflammatory molecules in a healthy population
inferred← citeshttps://doi.org/10.1371/journal.pone.0224591openalex-snapshot
Correction: Peripheral blood mononuclear cells extracts VEGF protein levels and VEGF mRNA: Associations with inflammatory molecules in a healthy population
inferred← citeshttps://doi.org/10.1517/13543784.2012.636351openalex-snapshot
Investigational VEGF antagonists for psoriasis
inferred← citeshttps://doi.org/10.15171/bi.2019.16openalex-snapshot
Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates
inferred← citeshttps://doi.org/10.1615/oncotherap.2022045086openalex-snapshot
Isoquinoline Alkaloids: Promising Natural Compounds for Targeting Angiogenesis and Metastasis in Colon Cancer
inferred← citeshttps://doi.org/10.18002/10612/5902openalex-snapshot
El papel de las hialuronidasas como quimiosensibilizadores en el tratamiento del cáncer colorrectal = Role of hyaluronidases as chemosensitizers in cancer treatment
inferred← citeshttps://doi.org/10.2217/crc.13.85openalex-snapshot
A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer
inferred← citeshttps://doi.org/10.3233/cbm-130344openalex-snapshot
Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival
inferred← citeshttps://doi.org/10.3389/fonc.2020.617837openalex-snapshot
Exosomal Long Non-Coding RNA: Interaction Between Cancer Cells and Non-Cancer Cells
inferred← citeshttps://doi.org/10.3390/cancers12010149openalex-snapshot
Prediction of Drug Efficacy in Colon Cancer Preclinical Models Using a Novel Ranking Method of Gene Expression
inferred← citeshttps://doi.org/10.3390/cancers14174067openalex-snapshot
BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies
inferred← citeshttps://doi.org/10.3390/cancers3010747openalex-snapshot
Recently Identified Biomarkers That Promote Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.3390/ijms221910260openalex-snapshot
Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
inferred← citeshttps://doi.org/10.3390/ijms26020649openalex-snapshot
Single-Cell RNA-Seq Uncovers Robust Glial Cell Transcriptional Changes in Methamphetamine-Administered Mice
inferred← citeshttps://doi.org/10.3390/pharmaceutics16091200openalex-snapshot
Improving Skin Cancer Treatment by Dual Drug Co-Encapsulation into Liposomal Systems—An Integrated Approach towards Anticancer Synergism and Targeted Delivery
inferred← citeshttps://doi.org/10.33915/etd.6887openalex-snapshot
Head and Neck Cancer Invasion: Contributions of Actin Regulatory Proteins and the Microenvironment
inferred← citeshttps://doi.org/10.3892/etm.2012.694openalex-snapshot
Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR
inferred← citeshttps://doi.org/10.3892/etm.2017.4692openalex-snapshot
Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer
inferred← citeshttps://doi.org/10.3892/ol.2016.4532openalex-snapshot
Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study)
inferred← citeshttps://doi.org/10.3892/ol.2018.8840openalex-snapshot
Inhibiting the proliferation and metastasis of hilar cholangiocarcinoma cells by blocking the expression of vascular endothelial growth factor with small interfering RNA
inferred← citeshttps://doi.org/10.3892/ol.2020.11489openalex-snapshot
Overexpression of LBX2 associated with tumor progression and poor prognosis in colorectal cancer
inferred← citeshttps://doi.org/10.3892/ol.2022.13542openalex-snapshot
BANCR positively regulates the HIF‑1α/VEGF‑C/VEGFR‑3 pathway in a hypoxic microenvironment to promote lymphangiogenesis in pancreatic cancer cells
inferred← citeshttps://doi.org/10.3892/or.2014.3169openalex-snapshot
MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine
inferred← citeshttps://doi.org/10.5306/wjco.v12.i11.1000openalex-snapshot
Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach
inferred← citeshttps://doi.org/10.5354/2735-7996.2020.69859openalex-snapshot
Clasificación molecular del cáncer colorrectal, su impacto pronóstico y terapéutico: un paso crucial hacia la medicina personalizada
inferred← citeshttps://doi.org/10.5772/intechopen.72318openalex-snapshot
The Hypoxia-Inducible Factor-1α in Angiogenesis and Cancer: Insights from the Drosophila Model
inferred← citeshttps://doi.org/10.70675/21aba473z09b8z4c23z941fz3b6d04b8b762openalex-snapshot
Implication de la sortiline dans la résistance des cellules cancéreuses au 5-Fluorouracile. Cas du cancer colorectal
inferred← citeshttps://doi.org/10.70675/f44144aaz4538z45abz9ce9za155e0c2e883openalex-snapshot
Personalised medicine approaches for investigation and application of new biomarkers
inferred← citeshttps://doi.org/10.7150/ijbs.59918openalex-snapshot
The Impact of TRPV1 on Cancer Pathogenesis and Therapy: A Systematic Review
inferred← citeshttps://doi.org/10.7150/thno.31716openalex-snapshot
Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR
inferred← citeshttps://doi.org/10.7759/cureus.71242openalex-snapshot
Expression Profiles of Integrin-Linked Kinase, Vascular Endothelial Growth Factor A, and Ephrin Type-A Receptor 2 in Colorectal Cancer Lymph Nodes
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.